Universal Health Services

Universal Health reported second-quarter results that included 8% net revenue growth, 5% adjusted EBITDA growth, and 12% adjusted EPS growth. With these lackluster operating profit trends, the company trimmed its 2026 guidance.

Why it matters: Probably recognizing that shares have fallen too much in early 2026, Universal rose slightly in early trading, despite its lower 2026 profit outlook of about 3% on an adjusted EPS basis at the midpoint. Specifically in early 2026, Universal is recognizing more headwinds related to a behavioral health facility in Texas that needs to be recertified, a slower ramp-up in its new hospital in Washington, D.C., higher professional and general liability expenses, and slightly lower volume assumptions that outweighed a higher-than-expected Medicaid supplemental payment from Florida for fiscal 2025. Without further Florida benefits contemplated in its guidance, Universal mildly lowered its adjusted EBITDA forecast (to $2.6 billion-$2.7 billion) and its adjusted EPS forecast (to $22.68-$23.65) on these pressures.

The bottom line: While we have trimmed our near-term forecast slightly on this news, our fair value estimate of $212 per share on narrow-moat Universal Health did not change materially, especially when considering cash flows generated since our last valuation update. Universal shares still look moderately undervalued to us, trading at a discount to fair value of nearly 25% and at an attractive traditional multiple of 7 times forward earnings. Management recognizes this disconnect between intrinsic value and market prices, too, and appears committed to significant share repurchases at these levels, which we appreciate. However, investors should know that the company faces upcoming regulatory hurdles, including Medicaid spending and supplemental payment cuts that start in 2027-28. Those hurdles could constrain caregiver profits in the near future due to pressure on both the top and bottom lines.

Our fair value estimate for Universal Health Services remains $212 per share, including the pending acquisition of Talkspace.

After a strong 2025, our major assumptions include revenue growth of 6% compounded annually through 2030, which looks roughly in line with the company's goals. On an organic basis, management aims for 5%-6% annualized growth in its acute services business and 6%-7% annualized growth in its behavioral health business. We do not include any unannounced acquisitions in our forecast.

We assume that margins face some pressure, and we estimate adjusted earnings per share growth at only 8% compounded annually through 2030, even when including significant share repurchases. In particular, we incorporate some margin constraints in the medium term, primarily as the "One Big Beautiful Bill" kicks in during 2027 (Medicaid enrollment challenges start) and 2028 (some supplemental Medicaid payments from states stop). Those could hurt both the top and bottom lines in those years, as UHS recognizes lower potential revenue and margins are squeezed by uncompensated care, especially at hospitals that must serve uninsured patients in their emergency rooms.

Additionally, UHS is facing a big legal challenge related to one doctor's alleged abuse at a particular facility. On a probability-weighted basis, we assume over $300 million in legal outflows net of insurance coverage due to that ongoing legal case by 2029 in our base-case assumptions.

We assign Universal Health Services a Narrow Economic Moat Rating. Despite upcoming headwinds for the caregiving industry related to new regulations for the individual exchanges and Medicaid, the firm’s economic profits look likely to remain above capital costs for our explicit 10-year forecast period, which corresponds well with our narrow moat rating. We see advantages in its hospital operations, where it generates operating margins in the top tier of US hospitals, as well as in its behavioral health segment, where it operates with even stronger margins and growth prospects than its hospital operations.

Overall, Universal Health Services uses its reputation for quality services, extensive physician relationships in its chosen communities, and convenient and efficient locations to attract demand for its acute care and behavioral health services. We view these factors as intangible asset-related advantages that help the company generate economic profits.

Acute Care Services

UHS’ acute care hospitals appear to rank strongly in third-party grading systems, with 80% of its evaluated hospitals earning A or B safety grades from Leapfrog Group in 2024. Also, U.S. News & World Report recognized two of its hospitals—George Washington University Hospital (in Washington, D.C.) and South Texas Health System Edinburg (in suburban McAllen)—as the Best in their regions while 21 of the 24 evaluated facilities earned at least one High Performing specialty designation.

These intangible asset-related advantages appear to help Universal Health Services earn above-average margins relative to other US healthcare systems. According to KFF, a leading US health policy organization, the average US hospital operating margin was 5% in 2023, or lower than the high-single digit margin that UHS’ hospitals enjoyed that year. This margin differential offers quantitative evidence of Universal’s competitive advantages in this segment, and we expect that positive differential to continue.

Behavioral Health Services

Given its higher margin and growth prospects, the behavioral health business appears to add to UHS’ overall competitive advantages, too, with a reputation-related moat source in its primarily inpatient behavioral health facilities, albeit with some notable exceptions. Positively, the firm scores well on its anonymous patient satisfaction surveys at the end of treatment, sporting a 4.42 overall satisfaction score out of 5.00, which the firm attributes to strong treatment outcomes. For example, survey responses included 91% feeling better than when admitted, 89% feeling satisfied with treatment, 89% being treated with dignity and respect, and 89% feeling their treatment goals and needs were met. Additionally, the segment’s overall net promoter score stood at 41.4 in 2024, or in the “great” category. These strong scores point to a solid overall reputation that helps this segment generate relatively high operating margins and economic profits, combined with the lower labor and medical technology costs in the behavioral health business compared with the acute care segment.

However, one of the firm’s key environmental, social, and governance-related risks appears to lie within this segment, too. UHS faces significant legal liabilities in the next few years related to alleged sexual abuse of many patients by a doctor in one of its facilities. Overall, we suspect the firm's strong financial position should help it manage its potential legal liabilities, which we estimate at several hundred million dollars outstanding on a probability-adjusted basis even after insurance coverage. However, the company may face other legal hurdles in the future if it cannot improve systemwide safety and controls, particularly in its inpatient facilities, where it often treats highly vulnerable patients.

An aging population could keep demand for future medical care strong at UHS' facilities.

The company's goal of expanding outpatient behavioral health services could boost growth in this relatively high-margin segment.

The balance sheet looks highly flexible right now, which should allow UHS to manage upcoming challenges.

Regulatory challenges could cut into the firm's profit potential starting in 2026-28, particularly in the Medicaid-related business.

Uncompensated care could spike in weak economic environments if uninsured rates rise.

Although under control in recent years, labor cost increases could eventually cut into future profits as well.